Jennerex is a clinical stage company focused on the discovery and the development of targeted cancer therapeutics. Jennerex intends to enter into both development and commercialization alliances with partners to bring the first-in-class cancer therapeutics to patients world-wide.

Jennerex has proprietary technology platforms which can generate highly targeted, oncolytic virus agents for the effective treatment of cancers. Jennerex is continually reviewing new discoveries and breakthrough technologies for in-license and collaborations opportunities.

Corporate Partners:

We seek to develop value-creating corporate alliances with commercial and academic partners. These alliances will be based on cutting-edge science, innovation and complementary attributes and skill sets. We will explore alliances in the areas of product discovery, development, manufacturing and commercialization in specific geographic regions world-wide.

Corporate Alliances: Product Development and Licensing Agreement

Green Cross Corp.

We currently have a product development and licensing agreement for JX-594 with Green Cross (Seoul, S. Korea) for the Korean market. Together we are focused on the development and eventual commercialization of JX-594 for liver cancers and other cancer indications in the Korean market. Green Cross is a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products.

Lee's Pharmaceuticals.

Jennerex is partnered with Lee's Pharmaceutical Holdings (HK Stock code: 8221) for JX-594 development and commercialization in China. Lee's is a public biopharmaceutical company with over 14 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets six products. "We are delighted to enter into this partnership with Lee's for JX-594 clinical development and commercialization. This represents an expansion of our regional partnering strategy," said David H. Kirn, M.D., President and Chief Executive Officer of Jennerex. "Partnering JX-594 in Asia is particularly advantageous to both Jennerex and our partners due to the product's lead indication for primary liver cancer, which has a very high incidence and high unmet medical need in countries throughout Asia. Our successful long-term partnership with Green Cross in South Korea is an example of this. Lee's is a highly capable development and commercial organization in China, and we look forward to working with Lee's toward the common goal of JX-594 approval and commercialization for the benefit of cancer patients."

Rex Medical

Jennerex has an alliance with Rex Medical, a manufacturer of advanced multi-pronged needles, for the use of this advanced needle for targeted intratumoral administration of JX-594. Jennerex exclusively uses Rex Medical Quadra-Fuse needles (“QF Needles”) for intratumoral injections of JX-594 in clinical development, and Rex Medical works collaboratively with Jennerex to effectively apply this technology to JX-594 clinical development.

“We are excited to be collaborating with Rex Medical, the market leader in this field, for application of Quadra-Fuse needle technology with JX-594. This is the first needle designed for optimizing therapeutic delivery of fluids/agents into target tissue zones. This innovative multi-pronged design allows us to precisely target distribution of JX-594 for optimal therapeutic effect. The result is an innovative and potentially landmark combination of a highly targeted biotherapeutic agent with a sophisticated medical device for targeted delivery.”

Quadra-fuse Multi-Pronged Needle for IT Injection:

Widespread, uniform distribution within liver tumors

Academic Alliances: Clinical and Discovery Research Collaborations

National Cancer Institute (Cell screening group)
National Cancer Institute of Canada (Clinical Trials Group)
University of Pittsburgh (David Bartlett, Chief of Surgery, Oncology)
Institute of Cancer Research/Royal Marsden Hospital (London, UK)
Oxford University (Dept. Clinical Pharmacology)
Ottawa Health Research Institute (Ottawa, Canada)